- Record: found
- Abstract: found
- Article: not found
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
Margaret M Redfield
1 ,
Horng H Chen ,
Barry A Borlaug ,
Marc J Semigran ,
Kerry L Lee ,
Gregory Lewis ,
Martin M LeWinter ,
Jean L Rouleau ,
David A Bull ,
Douglas L Mann ,
Anita Deswal ,
Lynne W Stevenson ,
Michael M Givertz ,
Elizabeth O Ofili ,
Christopher M O'Connor ,
G Michael Felker ,
Steven R Goldsmith ,
Bradley A Bart ,
Steven E McNulty ,
Jenny C Ibarra ,
Grace Lin ,
Jae K Oh ,
Manesh R Patel ,
Raymond J Kim ,
Russell P Tracy ,
Eric J Velazquez ,
Kevin J Anstrom ,
Adrian F Hernandez ,
Alice M Mascette ,
Eugene Braunwald
Mar 27 2013
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Studies in experimental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise capacity in heart failure with preserved ejection fraction (HFPEF).